The goal of this study was to gain further insight into the mechanisms involved in F-MuLV-induced neoplastic transformation of nonerythroid hematopoietic lineages. We have utilized the unique combination of F-MuLV and C57BL/6 in order to select for nonerythroid tumors. In addition, most of the tumors were generated in mice with myelomonocytic-specific expression of SV40 early region, which produces SV40T antigen, a multifunctional protein that can bind to and inactivate p53 and Rb. Thus, we are obviating the need for inactivation of either Rb or p53. One of the expectations in this study was to identify a small set of genes that cooperate with SV40 early region. 1 However, the results showed a large number of different insertions, with only three genes being found more than three times: Evi1 (17 times), Fim4 (four times) and Fim5 (five times). This suggests that a large number of different genes can cooperate with SV40 early region in the generation of myelomonocytic neoplasms, but it also precludes one from discerning a set of necessary or sufficient cooperating oncogenes or pathways in this model system. It is currently postulated that integration of ecotropic proviruses tends to occur at or near the 5 0 ends of transcriptionally active genes. Recent studies of proviral insertions occurring in retroviral marking studies in hematopoietic stem cells showed that proviral insertions occur in genes with known roles in growth regulation; 8 even in the absence of leukemia and using a replication defective virus. There is likely a selection process in which dominant clones harboring growth-promoting proviral insertions emerge out of the population of infected cells. In this study, 8 the retrovirus was nonreplicating, thus precluding acquisition of additional leukemogenic insertions that would complete the transformation process. That we identified 12 new CIS genes in this study probably reflects our use of a distinctive transgenic strain harboring SV40 early region under the control of the myelomonocyte-specific gp91phox promoter, which likely caused expansion of specific cells within the host hematopoietic system. Thus, the particular spectrum of insertions we obtained likely reflects the complement of genes that is transcriptionally active in the partially transformed myelomonocytic progenitors within the transgenic, preleukemic mouse. If true, this may yield insight into the pattern of gene expression in the myelomonocytic progenitor compartment.
Translocation t(12;21)(p13;q22), associated with favorable prognosis, is one of the most frequent structural chromosomal aberrations found in pediatric B-lineage acute lymphoblastic leukemia (ALL). This aberration leads to the fusion of exon 5 of Tel gene with exons 2 or 3 of Aml1 gene and results in long and short transcripts of Tel-Aml1. The short variant is differed from long form by 39 base pairs, that reflects the loss of the exon 2 of Aml1 gene during rearrangement or in the process of alternative splicing. 1 It is known that various splice-variants/transcripts of fusion genes can be associated with different clinical features. For example, leukemic clone expressing Bcr-Abl p210 is more responsive to Gleevec therapy comparing with Bcr-Abl p190 positive cells. 2 There are data concerning differences in prognosis of patients with various transcripts of Pml-Rara, expressed in acute promyelocytic leukemia. 3 Biological or clinical significance of various Tel-Aml1 transcripts is still unknown. Therefore, we evaluated expression of Tel-Aml1 transcript variants and their relationship to laboratory features of childhood ALL.
A total of 172 patients with B-lineage ALL (age 0.8-18.0 years) were included into this study. Diagnosis of ALL was verified according to FAB-classification. Immunological diagnosis was defined using scoring system devised by the European Group for the Immunological Classification of Leukemia (EGIL). Cytogenetic study was conducted using standard G-banding on slides with cultured leukemic cells. Expression of Tel-Aml1 was evaluated using nested RT-PCR.
The obtained data were analyzed using Statistica 6.0 software. Hypothesis of equation of two means was confirmed by criteria of Mann-Whitney U-test or w 2 . Results considered as significant at the value Po0.05. The study was approved by local Ethical Committee.
Expression of Tel-Aml1 was found in 20.3% of children with B-lineage ALL (35/172). In 91.4% (32/35) cases one of Tel-Aml1 variants prevailed, in two patients subtype of fusion gene was not determined and in one patient equal levels of both forms were found. The ratio of bone marrow samples from ALL patients with long and short variants was 3:1 (24/8). On the basis of transcript size differences, two subgroups of TelAml1-positive ALL (Tel-Aml1 pos ) were selected and possible associations of transcript variants to immunophenotypic and cytogenetic markers of leukemic cells were studied.
As it is shown in Table 1 , presence of long transcript was associated with the lower frequency of CD20 expression (Blineage marker of later differentiation stages) and higher frequency of CD34 (marker of early stages of hematopoietic differentiation) and myelomarkers CD13 and CD33 compared to cells expressing short transcript. Leukemic cells with long transcript were characterized also by a higher frequency of expression of CD13 and/or CD33 myeloid markers. In both subgroups significant negative correlation was found between CD20 and CD34 (r ¼ . Thus, we found that leukemic blasts with long transcript were the less differentiated (low level of CD20 and high one of CD34) and more frequently expressed myelomarkers. As differences in expression of immunophenotypic markers between clones with various transcripts were not absolute and both transcripts could be detected in leukemic cells obtained from the same patient, it should be investigated whether different transcripts are expressed in the same or in immunophenotypically diverse subpopulations of Tel-Aml1 pos leukemic clone. Metaphases were available for cytogenetic analysis in 62.5% (5/8) patients with short transcript and in 41.7% (10/24) with long one (Table 2 ). In all, 50% (5/10) of patients with long transcript had deletions of various locuses of the long arm of chromosome 6 and abnormalities of the second chromosome 12 were detected in 40% (4/10). Del(12)(p12) was found in two of four such cases. One patient (1/5) with short transcript had abnormality of the long arm of chromosome 6. There was no difference in frequency of aberrations with participation of chromosomes 6 and 12 between patients expressing various transcripts >ðP w 2 40:05Þ. Tel-Aml1 pos patients characterized by significantly higher frequency of abnormalities involving long arm of chromosome 6 comparing with Tel-Aml1 neg >ðP w 2 40:018Þ. The long transcript was associated with a more immature precursor B phenotype whereas the short transcript represented a more mature precursor B phenotype. Further studies should address the significance of additional genetic abnormalities in chromosomes 6 and 12 to the immature phenotype of blasts with a long transcript. Long 46,XY,der(6)t(6;12)(p25;q22)del(6)(q13q23),der(12)t(6;12)(p25;q22) [6] A small proportion of patients with chronic myeloid leukemia (CML) express unusual types of BCR-ABL transcript. In a recent paper, Demehri et al 1 pointed out that a BCR-ABL transcript with an e8a2 junction may be more frequent than other BCR-ABL mRNA variants. Moreover, a review of eight so far described cases suggested that e8a2-positive CML might be more aggressive than CML with typical e13a2 and e14a2 BCR-ABL mRNAs. We report here a novel form of e8a2 BCR-ABL transcript in a CML patient who was treated with imatinib and monitored using real-time RT-PCR.
A 43-year-old man was diagnosed with CML in August 2004. At presentation, the spleen was palpable (3 cm below costal margin). The hematological parameters were the following: white blood cells, 197 Â 10 9 /l with a differential count of 7% blasts, 7% promyelocytes, 15% metamyelocytes, 23% myelo- 0 end of ABL exon 2, the second line is the sequence of the neo-exon from BCR intron 8 and the third line is the sequence of acceptor and donor splice sites surrounding this new exon. Canonical dinucleotides GT and AG at the 5 0 and 3 0 intron boundaries are given in bold. The scores for the splice sites calculated using the splice site detector program NetGene2 are indicated.
